Form 4: Neurocrine Biosciences Director Richard F. Pops Acquires Restricted Stock Units

Director Richard F. Pops acquired 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences, Inc. on May 22, 2024, which will vest on May 22, 2025.

Summary

• On May 22, 2024, Richard F. Pops, a director of Neurocrine Biosciences Inc., acquired 2,869 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Neurocrine Biosciences' common stock upon vesting.
• The RSUs will vest in full on May 22, 2025.
• Following the transaction, Mr. Pops directly owns 2,869 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a standard disclosure of stock units acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider activity.

Positives

• The acquisition of RSUs by a director may indicate confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the vesting of the RSUs on May 22, 2025, suggests a continued relationship between the director and the company.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions. It provides transparency into the holdings of company directors and their alignment with shareholder interests. Such filings are common in the biotechnology industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The vesting schedule of one year for the RSUs is fairly typical.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's holdings.
• The vesting of RSUs aligns the director's interests with those of the shareholders.

Key Dates